PAVmed Inc. (PAVM)
NASDAQ: PAVM · IEX Real-Time Price · USD
1.010
-0.030 (-2.88%)
At close: Jul 19, 2024, 4:00 PM
1.080
+0.070 (6.93%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
PAVmed Revenue
PAVmed had revenue of $3.02M in the twelve months ending March 31, 2024, with 375.71% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.01M with 126.46% year-over-year growth. In the year 2023, PAVmed had annual revenue of $2.45M with 550.40% growth.
Revenue (ttm)
$3.02M
Revenue Growth
+375.71%
P/S Ratio
3.16
Revenue / Employee
$28,187
Employees
107
Market Cap
9.53M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.45M | 2.08M | 550.40% |
Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pieris Pharmaceuticals | 40.93M |
Plus Therapeutics | 6.08M |
Elevai Labs | 2.18M |
Mangoceuticals | 844.87K |
Nexalin Technology | 158.86K |
Silo Pharma | 72.10K |
ABVC BioPharma | 25.36K |
PAVM News
- 10 days ago - Lucid Diagnostics Launches New Corporate Website - PRNewsWire
- 20 days ago - Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population - PRNewsWire
- 5 weeks ago - PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute - PRNewsWire
- 5 weeks ago - 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing - PRNewsWire
- 2 months ago - PAVmed Provides Business Update and First Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall - PRNewsWire
- 2 months ago - Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors - PRNewsWire